article · European Journal of Gastroenterology & Hepatology

Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis

Maha Elsabaawy
Asmaa A. Mahmoud
Dalia Elsabaawy
Medhat Assem
Hanaa Badran
Amr Ragab

20242 citationsBenha University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Combined midodrine with rifaximin represents an endowment to patients with DLC with spectacular improvements in synthetic liver functions, along with improved quality of life, and survival.

Research topics

Liver Disease and Transplantation
Liver Disease Diagnosis and Treatment
Organ Transplantation Techniques and Outcomes

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1097/meg.0000000000002797

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.